Ocugen (OCGN) Shares Outstanding (2014 - 2026)
Ocugen's (OCGN) quarterly Shares Outstanding (Entity) came in at $338.4 million in Q1 2026, up 15.84% YoY from $292.1 million in Q1 2025, and up 8.3% on a QoQ basis from $312.5 million in Q4 2025.
Ocugen (OCGN) Shares Outstanding (2014 - 2026) Analysis & Trends
Ocugen (OCGN) has 13 years of Shares Outstanding (Entity) data on file, last reported at $338.4 million in Q1 2026.
- Quarterly Shares Outstanding (Entity) rose 15.84% year-over-year to $338.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $338.4 million (up 15.84% YoY) and the FY2025 annual result came in at $312.5 million, up 7.21% from the prior year.
- Shares Outstanding (Entity) rose to $338.4 million in Q1 2026, from $312.5 million in the prior quarter.
- In the past five years, Shares Outstanding (Entity) ranged from a high of $338.4 million in Q1 2026 to a low of $215.8 million in Q1 2022.
- A 5-year average of $265.4 million and a median of $257.4 million in 2024 frame the typical range for Shares Outstanding (Entity).
- Annual changes were most pronounced in 2023 — Shares Outstanding (Entity) advanced 18.65% — and 2024, when it grew 0.36%.
- Tracing OCGN's Shares Outstanding (Entity) over 5 years: stood at $221.7 million in 2022, then advanced by 15.77% to $256.7 million in 2023, then grew by 13.56% to $291.5 million in 2024, then advanced by 7.21% to $312.5 million in 2025, then rose by 8.3% to $338.4 million in 2026.
- The last three Shares Outstanding (Entity) figures came in at $338.4 million (Q1 2026), $312.5 million (Q4 2025), and $312.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 62.19 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 210.89 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.45 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 25.05 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 445.06 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 133.61 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 217.35 Mn |
| 10 | Ocugen | 457.71 Mn | 357.61 Mn | - | 338.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 338.68 Mn |
| Mar 31, 2026 | 327.54 Mn |
| Dec 31, 2025 | 300.17 Mn |
| Sep 30, 2025 | 304.00 Mn |
| Jun 30, 2025 | 292.07 Mn |
| Mar 31, 2025 | 292.00 Mn |
| Dec 31, 2024 | 271.00 Mn |
| Sep 30, 2024 | 278.17 Mn |
| Jun 30, 2024 | 257.35 Mn |
| Mar 31, 2024 | 257.23 Mn |
| Dec 31, 2023 | 244.33 Mn |
| Sep 30, 2023 | 256.49 Mn |
| Jun 30, 2023 | 238.31 Mn |
| Mar 31, 2023 | 225.52 Mn |
| Dec 31, 2022 | 214.60 Mn |
| Sep 30, 2022 | 216.59 Mn |
| Jun 30, 2022 | 215.86 Mn |
| Mar 31, 2022 | 205.69 Mn |
| Dec 31, 2021 | 195.01 Mn |
| Sep 30, 2021 | 198.79 Mn |